Ariceum Therapeutics Email Format

Biotechnology ResearchBerlin, Germany2-10 Employees

Ariceum Therapeutics is a private, clinical-stage biotechnology company focused on radiopharmaceuticals for the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Headquartered in Berlin, Germany, the company operates across Germany, Switzerland, Australia, the United Kingdom, and the United States and employs 11-50 people. Its lead candidate SSO110 (satoreotide) is labeled with Lutetium-177 and Actinium-225 and functions as an antagonist of the somatostatin type 2 receptor (SSTR2), aiming to provide diagnostic imaging and targeted radionuclide therapy for aggressive neuroendocrine tumors. Ariceum is also developing a radiolabeled PARP inhibitor, ATT001, in Phase 1 trials under the name CITADEL-123, a program that traces back to the Theragnostics Ltd acquisition completed in 2023. The company was launched in 2021 and has acquired all rights to satoreotide from Ipsen, which remains a shareholder. It is supported by specialist investors and has partnered with industry collaborators, including a supply arrangement with NorthStar for Ac-225 and a collaboration with UCB SA.

Get verified Ariceum Therapeutics emails free

Company overview Employee directory